These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38195959)

  • 21. Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca
    Ottesen AH; Carlson CR; Eken OS; Sadredini M; Myhre PL; Shen X; Dalhus B; Laver DR; Lunde PK; Kurola J; Lunde M; Hoff JE; Godang K; Sjaastad I; Pettilä V; Stridsberg M; Lehnart SE; Edwards AG; Lunde IG; Omland T; Stokke MK; Christensen G; Røsjø H; Louch WE
    Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e007045. PubMed ID: 30943765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways.
    Zhang Y; Shang Z; Liu A
    Amino Acids; 2021 Oct; 53(10):1533-1543. PubMed ID: 34494132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation.
    Morishige S; Takahashi-Yanaga F; Ishikane S; Arioka M; Igawa K; Kuroo A; Tomooka K; Shiose A; Sasaguri T
    Biochem Pharmacol; 2019 Oct; 168():82-90. PubMed ID: 31229551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type III Transforming Growth Factor-β Receptor Drives Cardiac Hypertrophy Through β-Arrestin2-Dependent Activation of Calmodulin-Dependent Protein Kinase II.
    Lou J; Zhao D; Zhang LL; Song SY; Li YC; Sun F; Ding XQ; Yu CJ; Li YY; Liu MT; Dong CJ; Ji Y; Li H; Chu W; Zhang ZR
    Hypertension; 2016 Sep; 68(3):654-66. PubMed ID: 27432858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice.
    Ling H; Zhang T; Pereira L; Means CK; Cheng H; Gu Y; Dalton ND; Peterson KL; Chen J; Bers D; Brown JH
    J Clin Invest; 2009 May; 119(5):1230-40. PubMed ID: 19381018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of FMS-like tyrosine kinase 3 protects against isoprenaline-induced cardiac hypertrophy by improving autophagy and mitochondrial dynamics.
    Jiang X; Zhang K; Gao C; Ma W; Liu M; Guo X; Bao G; Han B; Hu H; Zhao Z
    FASEB J; 2022 Dec; 36(12):e22672. PubMed ID: 36440960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrated miRNA-mRNA networks underlie attenuation of chronic β-adrenergic stimulation-induced cardiac remodeling by minocycline.
    Russell JJ; Mummidi S; DeMarco VG; Grisanti LA; Bailey CA; Bender SB; Chandrasekar B
    Physiol Genomics; 2024 Apr; 56(4):360-366. PubMed ID: 38314697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload.
    Backs J; Backs T; Neef S; Kreusser MM; Lehmann LH; Patrick DM; Grueter CE; Qi X; Richardson JA; Hill JA; Katus HA; Bassel-Duby R; Maier LS; Olson EN
    Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2342-7. PubMed ID: 19179290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heart failure.
    Sag CM; Wadsack DP; Khabbazzadeh S; Abesser M; Grefe C; Neumann K; Opiela MK; Backs J; Olson EN; Brown JH; Neef S; Maier SK; Maier LS
    Circ Heart Fail; 2009 Nov; 2(6):664-75. PubMed ID: 19919992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRABP1 protects the heart from isoproterenol-induced acute and chronic remodeling.
    Park SW; Persaud SD; Ogokeh S; Meyers TA; Townsend D; Wei LN
    J Endocrinol; 2018 Mar; 236(3):151-165. PubMed ID: 29371236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model.
    Bin-Dayel AF; Abdel Baky NA; Fadda LM; Mohammad RA; Al-Mohanna F
    Toxicol Mech Methods; 2016 Feb; 26(2):122-31. PubMed ID: 26982530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of CaMKIIdelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure.
    Kushnir A; Shan J; Betzenhauser MJ; Reiken S; Marks AR
    Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10274-9. PubMed ID: 20479242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
    Karam S; Margaria JP; Bourcier A; Mika D; Varin A; Bedioune I; Lindner M; Bouadjel K; Dessillons M; Gaudin F; Lefebvre F; Mateo P; Lechène P; Gomez S; Domergue V; Robert P; Coquard C; Algalarrondo V; Samuel JL; Michel JB; Charpentier F; Ghigo A; Hirsch E; Fischmeister R; Leroy J; Vandecasteele G
    Circulation; 2020 Jul; 142(2):161-174. PubMed ID: 32264695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcium/calmodulin-dependent protein kinase II regulation of I
    Shugg T; Johnson DE; Shao M; Lai X; Witzmann F; Cummins TR; Rubart-Von-der Lohe M; Hudmon A; Overholser BR
    Heart Rhythm; 2018 Jun; 15(6):895-904. PubMed ID: 29410121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CaMKIIδ post-translational modifications increase affinity for calmodulin inside cardiac ventricular myocytes.
    Simon M; Ko CY; Rebbeck RT; Baidar S; Cornea RL; Bers DM
    J Mol Cell Cardiol; 2021 Dec; 161():53-61. PubMed ID: 34371035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xanthohumol attenuates isoprenaline-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.
    Sun TL; Li WQ; Tong XL; Liu XY; Zhou WH
    Eur J Pharmacol; 2021 Jan; 891():173690. PubMed ID: 33127362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissection of mechanisms of Chinese medicinal formula Si-Miao-Yong-an decoction protects against cardiac hypertrophy and fibrosis in isoprenaline-induced heart failure.
    Zhao Y; Jiang Y; Chen Y; Zhang F; Zhang X; Zhu L; Yao X
    J Ethnopharmacol; 2020 Feb; 248():112050. PubMed ID: 31265887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced expression of β3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase.
    Belge C; Hammond J; Dubois-Deruy E; Manoury B; Hamelet J; Beauloye C; Markl A; Pouleur AC; Bertrand L; Esfahani H; Jnaoui K; Götz KR; Nikolaev VO; Vanderper A; Herijgers P; Lobysheva I; Iaccarino G; Hilfiker-Kleiner D; Tavernier G; Langin D; Dessy C; Balligand JL
    Circulation; 2014 Jan; 129(4):451-62. PubMed ID: 24190960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy.
    Hardt SE; Tomita H; Katus HA; Sadoshima J
    Circ Res; 2004 Apr; 94(7):926-35. PubMed ID: 15001529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy.
    Liu L; An X; Li Z; Song Y; Li L; Zuo S; Liu N; Yang G; Wang H; Cheng X; Zhang Y; Yang X; Wang J
    Cardiovasc Res; 2016 Jul; 111(1):56-65. PubMed ID: 27084844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.